Targovax is a clinical stage immuno-oncology company, which engages in the development of targeted immunotherapies for cancer patients. It is developing a peptide-based targeted immunotherapy platform for patients with RAS-mutated cancers; and a virus-based oncolytic immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. The Company’s product candidates include TG01, which is in Phase I/II clinical trial for the treatment of patients with resected adenocarcinoma of the pancreas; TG02 that is in Phase I clinical trial for the treatment of colorectal cancer; and ONCOS-102 that is in Phase I/II study for the treatment of mesothelioma, as well as for ovarian cancer and soft tissue sarcoma.
|Employees (est.) (Feb 2019)||26||(-3%)|
|Share Price (May 2020)||KR7.9||(-1%)|
Market capitalization (29-May-2020)
Closing stock price (29-May-2020)
|Company Name||Date||Deal Size|
|Oncos Therapeutics||July 02, 2015|
Targovax has 598 Twitter Followers. The number of followers has increased 5.6% month over month and increased 9.5% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
Who are Targovax key executives?
Targovax's key executives are Øystein Soug, Patrick Vink and Erik Digman Wiklund.
How many employees does Targovax have?
Targovax has 26 employees.
Who are Targovax competitors?
Competitors of Targovax include Pantherna Therapeutics, Medicenna Therapeutics and Fab'entech.
Where is Targovax headquarters?
Targovax headquarters is located at 2C Lilleakerveien, Ullern.
Where are Targovax offices?
Targovax has an office in Ullern.
How many offices does Targovax have?
Targovax has 1 office.
Receive alerts for 300+ data fields across thousands of companies